01:50 , Apr 8, 2006 |  BC Extra  |  Company News

Isis out-licenses ISIS 301012

Late on Friday, ISIS said it out-licensed ISIS 301012 and two preclinical diabetes compounds to Symphony GenIsis. Symphony GenIsis was formed by Symphony Capital, which, along with undisclosed investors, provided an initial investment of $75...